Trium Capital LLP Hille Vax, Inc. Transaction History
Trium Capital LLP
- $830 Million
- Q2 2025
A detailed history of Trium Capital LLP transactions in Hille Vax, Inc. stock. As of the latest transaction made, Trium Capital LLP holds 395,188 shares of HLVX stock, worth $821,991. This represents 0.09% of its overall portfolio holdings.
Number of Shares
395,188
Previous 378,205
4.49%
Holding current value
$821,991
Previous $548,000
43.43%
% of portfolio
0.09%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding HLVX
# of Institutions
69Shares Held
34.6MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$22.1 Million0.97% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$10.2 Million0.46% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$4.35 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.95MShares$4.06 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.92 Million0.07% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $69.5M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.